GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,533.50
+17.50 (+1.15%)
At close: 5:14PM BST
Stock chart is not supported by your current browser
Previous Close1,516.00
Open1,518.50
Bid1,532.00 x 175400
Ask1,534.00 x 417900
Day's Range1,516.00 - 1,538.00
52 Week Range1,444.00 - 1,724.50
Volume7,149,697
Avg. Volume7,942,240
Market Cap74.46B
Beta1.15
PE Ratio (TTM)39.22
EPS (TTM)39.1
Earnings DateOct 25, 2017
Dividend & Yield1.01 (5.14%)
Ex-Dividend Date2017-08-10
1y Target Est1,719.73
  • Market Realist5 hours ago

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks2 days ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • Reuters5 days ago

    GlaxoSmithKline's shingles vaccine gets approval in Canada

    (Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...

  • CNBC6 days ago

    Pharma companies are starting to recruit top talent from tech giants like Google and LinkedIn

    Pharma companies are recruiting technologists to help speed up their drug discovery and development processes.

  • The Wall Street Journal7 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • Pfizer weighs $15 bln sale of consumer healthcare business
    Reuters8 days ago

    Pfizer weighs $15 bln sale of consumer healthcare business

    The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.

  • May to consult business leaders on Brexit
    Reuters10 days ago

    May to consult business leaders on Brexit

    Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • 3 High-Yield Healthcare Stocks
    Motley Fool10 days ago

    3 High-Yield Healthcare Stocks

    If you're on the hunt for above-average yields, these three healthcare stocks should be on your radar.

  • Reuters12 days ago

    FTSE at two-month peak as sterling falters

    British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.

  • Financial Times12 days ago

    [$$] Consumer drugs do not always work for big pharma 

    There is a big difference between a cold and the flu - and it is a distinction on which drugmakers have long relied when selling throat lozenges and fortified lemon drinks over the counter for one condition ...

  • Market Realist13 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • Drug industry gives up legal battle over new UK cost curbs
    Reuters13 days ago

    Drug industry gives up legal battle over new UK cost curbs

    Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Market Realist13 days ago

    Performance of GlaxoSmithKline’s Consumer Healthcare Segment

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.

  • Market Realist13 days ago

    Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

    The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.

  • Capital Cube14 days ago

    GlaxoSmithKline Plc – Value Analysis (LONDON:GSK) : October 4, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives GlaxoSmithKline Plc a score of 63. Our analysis is based on comparing GlaxoSmithKline Plc with the following peers – AstraZeneca PLC, Shire PLC, Hikma Pharmaceuticals Plc and Consort Medical Plc (AZN-GB, SHP-GB, HIK-GB and CSRT-GB). Investment Outlook GlaxoSmithKline Plc has a fundamental score of 63 and has ... Read more (Read more...)

  • Market Realist14 days ago

    Quarterly Performance for GlaxoSmithKline’s HIV Business

    HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.

  • Market Realist14 days ago

    GlaxoSmithKline’s Pharmaceuticals Segment in 2Q17

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment reported a 3.0% rise in revenues at constant exchange rates and a 9.0% positive impact of foreign exchange in 2Q17.

  • Market Realist15 days ago

    GlaxoSmithKline’s Quarterly Revenues

    GlaxoSmithKline (GSK) reported a 12.0% rise in revenues to 7.3 billion pounds in 2Q17 compared to 6.5 billion pounds in 2Q16.

  • Market Realist15 days ago

    GlaxoSmithKline’s Recent 3Q17 Developments

    On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.

  • GlobeNewswire15 days ago

    Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK

    Transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017. GAITHERSBURG, Md., Oct. 03, 2017-- Emergent BioSolutions Inc. announced ...

  • GlaxoSmithKline Plc breached its 50 day moving average in a Bullish Manner : GSK-GB : October 3, 2017
    Capital Cube15 days ago

    GlaxoSmithKline Plc breached its 50 day moving average in a Bullish Manner : GSK-GB : October 3, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for GlaxoSmithKline Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Reuters16 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

  • Reuters16 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

  • Reuters16 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    A U.S. judge has dismissed a lawsuit by two former corporate investigators who accused GlaxoSmithKline Plc (GSK) of misleading them into investigating a whistleblower in China, leading to their arrest amid a bribery scandal involving the drugmaker. U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee.

  • Benzinga20 days ago

    Attention Biotech Investors, Here's Your PDUFA Primer For October

    The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In ...